drugset / Trial / NCT06447090
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation. The main questions it aims to answer are: The safety and efficacy of VMAC combined with DLI in the treatment of allo HSCT recurrence in AML patients;
Timeline
- Start
- 2024-04-12
- Primary completion
- 2027-05-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Mitoxantrone hydrochloride liposome | Unknown | 30 mg/m2 | — |
| Subject | Veneclatra | Unknown | 100 mg | — |
| Subject | Veneclatra | Unknown | 400 mg | — |